X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
dbDNA technology can deliver high purity GMP DNA in a small footprint at unprecedented speed and is ideally positioned to enable rapid individual personalized vaccines for non-small cell lung neoplasm patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Liverpool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2024
Details:
VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).
Lead Product(s): VMB-100
Therapeutic Area: Urology Product Name: VMB-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Versameb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA will be used as an in vitro transcription template for mRNA production in the manufacturing of a cell therapy product.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Odimma Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2022
Details:
Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Voyager Therapeutics, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 15, 2022
Details:
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Lonza Capsugel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2022
Details:
Under the license agreement, Pfizer gains rights to Touchlight’s enzymatic doggybone DNA (dbDNA™) patent portfolio for worldwide use in Pfizer’s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 06, 2022
Details:
The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.
Lead Product(s): VMB-100
Therapeutic Area: Urology Product Name: VMB-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Versameb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2022
Details:
The vaccine targets multiple viral antigens with the aim of generating an antibody and T-cell based immune response, whose breadth more closely mimics that of convalescent patients.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2020
Details:
The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Lead Product(s): TGL-100
Therapeutic Area: Oncology Product Name: TGL-100
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Cancer Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
